Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a health and wellness company specializing in the formulation of a suite of medicinal mushroom health products, as well as novel delivery platforms for the pharmaceutical and nutraceutical industries, today announced the appointment of Dr. Joseph Gabriele, a molecular pharmacologist specializing in signal transduction within the central nervous system, to its Special Advisory Committee. According to the update, Dr. Gabriele, PhD, specializes in the areas of molecular pharmacology, transdermal delivery and formulation chemistry with pharmaceutical, natural molecules and will champion the company’s development and commercialization of rapid onset treatments capable of improving health outcomes. “Dr. Gabriele’s established research credentials, entrepreneurial nature and relentless pursuit of medical innovation represents the desired skill sets that Champignon needs as we accelerate our accession into the psychedelic medicine arena,” Champignon Brands CEO Gareth Birdsall said in the news release. “The appointment of Dr. Gabriele equips us with both a celebrated medical researcher, as well as a seasoned CPG formulation specialist, which will allow for the continued development of our mushroom-infused health products, novel delivery systems and eventual drug discovery initiatives. Champignon Brands is set to emerge as an impact investment that may not only change people’s lives but may also revolutionize the face of medicine as we know it today.”
To view the full press release, visit http://ibn.fm/GVLMY
About Champignon Brands Inc.
Champignon Brands Inc. (CSE: SHRM) is a research driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes for indications such as depression and Post Traumatic Stress Disorder (“PTSD”), as well as substance and alcohol use disorders. Champignon continues to be inspired by sustainability, as its medicinal mushroom infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.
NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.